department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Camptosar · pharmadog

pharmadog
drugs
Camptosar

drug

patient view →

Camptosar

Marketedupdated 2mo ago

by $PFE PFIZER INC

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 37 investigational indications.

indications

investigational

Colorectal Cancer

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Camptosar

generic

irinotecan hydrochloride

MOA

DNA topoisomerase I inhibitor

indication

Colorectal Cancer

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 6, 2027

183 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

Oct 15, 2036formulationUS 10456360
Oct 15, 2036formulationUS 10993914
Oct 15, 2036formulationUS 12059497
Aug 19, 2036method-of-use (U-3824)US 11344552
Jun 12, 2033method-of-use (U-1848)US 10980795
Jun 12, 2033method-of-use (U-1848)US 11369597
Jun 12, 2033method-of-use (U-1848)US 12364691
Jun 12, 2033method-of-use (U-1848)US 9339497
Jun 12, 2033method-of-use (U-1856)US 9364473
Jun 12, 2033method-of-use (U-1899)US 9452162
Jun 12, 2033method-of-use (U-1848)US 9492442
Jun 12, 2033method-of-use (U-1848)US 9717724
Aug 29, 2028compositionUS 81478672.1y
Jan 6, 2027compositionUS 8329213183d

FDA exclusivities (2)

Feb 13, 2031ODE-463Orphan Drug (7y)4.6y
Feb 13, 2027I-932Indication (3y)221d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 2m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying Camptosar

phase3A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)not yet recruitingn=538
phase3QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinomarecruitingn=466
phase1Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgerycompletedn=47
phase3A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancerrecruitingn=1,000
phase2A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancerterminatedn=21
phase3A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatmentnot yet recruitingn=438
phase3SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinomanot yet recruitingn=436
N/AChemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancernot yet recruitingn=136

more trials →